Phase I-II Study of Bendamustine in Patients with Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS).

Trial Profile

Phase I-II Study of Bendamustine in Patients with Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2012

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Mar 2012 Actual patient number 27 added as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual initiation date changed from May 2008 to Nov 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top